Summit Therapeutics Overview
Summit Therapeutics (SMMT) has a ROE of -135.89%, below the sector sector average of -5.87%.
Get informed when a big investor buys or sells
+ Follow-135.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for SMMT is -135.89%. That is below the sector sector average of -5.87%. Investors often review this figure alongside Summit Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, SMMT currently prints -135.89% for ROE, while the sector average sits near -5.87%. That is roughly 2215.6% below the sector mean. Large gaps often invite a closer look at Summit Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Summit Therapeutics converts resources into returns. At -135.89%, SMMT may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SMMT's ROE (-135.89%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
